BioVaxys Technology Corp. (BVAXF)
USD 0.05
(7.06%)
USD 0.05
(7.06%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | 2.4 Million | 4.08 Million | 6.44 Million | 1.09 Million | 229.9 Thousand |
| Selling, General and Administrative Expenses | 2.26 Million | 3.11 Million | 5.71 Million | 859.61 Thousand | 229.9 Thousand |
| Research and Development Expenses | 133.73 Thousand | 962.7 Thousand | 726.05 Thousand | 238.77 Thousand | - |
| Other Expenses | - | - | - | - | - |
| Cost and Expenses | 2.4 Million | 4.08 Million | 6.44 Million | 1.09 Million | 229.9 Thousand |
| Operating Income | -2.4 Million | 3.57 Million | -6.41 Million | -1.09 Million | -229.69 Thousand |
| Interest Expense | - | - | - | - | - |
| Income Tax Expense | - | 7.64 Million | 9926.75 | 71.68 Thousand | 29.66 |
| Earnings before Tax | -7.68 Million | -11.72 Million | -6.45 Million | -1.1 Million | -230.12 Thousand |
| Net Income | -7.68 Million | -11.72 Million | -6.45 Million | -1.17 Million | -230.12 Thousand |
| Earnings Per Share Basic | -0.06 | -0.12 | -0.08 | -0.04 | -0.02 |
| Earnings Per Share Diluted | -0.06 | -0.12 | -0.08 | -0.04 | -0.02 |
| Weighted Average Shares Outstanding | 134.14 Million | 98.18 Million | 82.93 Million | 30.04 Million | 11.01 Million |
| Weighted Average Shares Outstanding (Diluted) | 134.14 Million | 98.17 Million | 82.93 Million | 28.21 Million | 10.38 Million |
| Gross Margin | - | - | - | - | - |
| EBIT Margin | - | - | - | - | - |
| Profit Margin | - | - | - | - | - |
| EBITDA | - | 3.57 Million | - | - | - |
| Earnings Before Tax Margin | - | - | - | - | - |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| Operating Expenses | 802.18 Thousand | 539.18 Thousand | 370.7 Thousand | 4.19 Million | 6.45 Million | 562.22 Thousand |
| Selling, General and Administrative Expenses | 802.18 Thousand | 539.18 Thousand | 370.7 Thousand | 4.22 Million | - | 309.56 Thousand |
| Research and Development Expenses | - | - | - | -31.16 Thousand | - | 31.79 Thousand |
| Other Expenses | - | 53.04 Thousand | 880.38 Thousand | - | - | - |
| Cost and Expenses | 802.18 Thousand | 539.18 Thousand | 370.7 Thousand | 4.19 Million | 6.45 Million | 562.22 Thousand |
| Operating Income | -802.18 Thousand | -539.19 Thousand | -370.7 Thousand | -4.19 Million | -6.45 Million | 454.33 Thousand |
| Interest Expense | - | - | - | - | - | - |
| Income Tax Expense | - | -486.14 Thousand | -43.27 Thousand | -43.81 Thousand | -167.89 Thousand | 1.01 Million |
| Earnings before Tax | -1.18 Million | -542.38 Thousand | 518.04 Thousand | -3.66 Million | -7.68 Million | -1.57 Million |
| Net Income | -1.18 Million | -542.38 Thousand | 518.04 Thousand | -3.66 Million | -7.68 Million | -1.57 Million |
| Earnings Per Share Basic | -0.01 | -0.00 | 0.00 | -0.03 | - | -0.01 |
| Earnings Per Share Diluted | -0.01 | -0.00 | 0.00 | -0.03 | - | -0.01 |
| Weighted Average Shares Outstanding | 220.08 Million | 208.24 Million | 145.26 Million | 145.11 Million | 134.14 Million | 146.81 Million |
| Weighted Average Shares Outstanding (Diluted) | 220.07 Million | 208.24 Million | 145.26 Million | 145.11 Million | 134.14 Million | 146.81 Million |
| Gross Margin | - | - | - | - | - | - |
| EBIT Margin | - | - | - | - | - | - |
| Profit Margin | - | - | - | - | - | - |
| EBITDA | - | -539.19 Thousand | -370.7 Thousand | -4.19 Million | - | 454.33 Thousand |
| Earnings Before Tax Margin | - | - | - | - | - | - |
ITI
MUEL
3558
ARG
APEUF
605138